Mind Medicine (mindmed) INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Robert Barrow, Chief Executive Officer and a Director of Mind Medicine (MindMed) Inc., received 375,000 shares of common stock on August 12, 2026.
Daniel Karlin, Chief Medical Officer of Mind Medicine (MindMed) Inc., received 100,000 shares of common stock on August 12, 2026.
Mark Sullivan, Chief Legal Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Matthew T. Wiley, Chief Commercial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Brandi Roberts, Chief Financial Officer of Mind Medicine (MindMed) Inc., received 62,500 shares of common stock on August 12, 2026.
Definium Therapeutics Chief Legal Officer Mark Sullivan sold 13,008 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.
Brandi Roberts, Chief Financial Officer of Definium Therapeutics, Inc., sold 3,013 common shares to cover tax withholding obligations as part of a pre-established Rule 10b5-1 trading plan.
Definium Therapeutics CEO Robert Barrow sold 29,208 common shares to cover tax obligations under a Rule 10b5-1 plan.
Definium Therapeutics Chief Medical Officer Daniel Karlin sold 10,035 common shares for $45.03 per share on June 25, 2026, to cover tax withholding obligations under a Rule 10b5-1 plan.
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley sold 2,867 common shares to cover tax withholding obligations under a Rule 10b5-1 plan.
Definium Therapeutics Director Roger Crystal reports acquisition of restricted stock units and stock options, alongside beneficial ownership of common shares.
David W. Gryska, a Director at Definium Therapeutics, Inc., has reported the acquisition of restricted stock units and the exercise of stock options.
Carol Vallone, a Director at Definium Therapeutics, Inc., has acquired 4,666 common shares and a stock option for 19,188 shares, as detailed in a Form 4 filing.
Andreas Krebs, a Director at Definium Therapeutics, Inc., reported the acquisition of 4,666 restricted stock units and the grant of 19,188 stock options on June 11, 2026.
Roger Adsett, a Director at Definium Therapeutics, Inc., reported the acquisition of 3,555 common shares and a stock option for 14,620 shares.
Suzanne Bruhn, a Director at Definium Therapeutics, Inc., reported transactions involving stock options and restricted stock units.
Definium Therapeutics' Chief Medical Officer, Daniel Karlin, sold 8,018 common shares at a weighted average price of $18.47 to cover tax obligations from vested restricted stock units.
Definium Therapeutics' Chief Legal Officer, Mark Sullivan, sold 10,702 common shares at a weighted average price of $18.47 to cover tax obligations from vested restricted stock units.
Definium Therapeutics CEO Robert Barrow sold 24,431 common shares on March 25, 2026, to cover tax obligations from vested restricted stock units.
Definium Therapeutics, Inc. Chief Financial Officer Brandi Roberts was granted 150,000 restricted stock units, vesting quarterly starting June 2026.
Definium Therapeutics' Chief Legal Officer, Mark Sullivan, was granted 125,000 Restricted Stock Units, vesting quarterly starting June 2026.
Definium Therapeutics' Chief Medical Officer, Daniel Karlin, was granted 150,000 restricted stock units, aligning executive incentives with long-term company performance.
Definium Therapeutics CEO Robert Barrow was granted 320,000 restricted stock units, increasing his beneficial ownership to 1,098,477 common shares.
Definium Therapeutics director Roger Adsett received a grant of 50,000 stock options with a vesting schedule over three years.
Mind Medicine's Chief Medical Officer, Daniel Karlin, sold 5,600 common shares for $13.1469 each to cover tax obligations related to vested restricted stock units.
MindMed CEO Robert Barrow sold 25,791 common shares on December 26, 2025, to cover tax obligations from vested restricted stock units.
Mind Medicine's Chief Legal Officer, Mark Sullivan, sold 11,276 common shares on December 26, 2025, to cover tax obligations from vested restricted stock units.
Mind Medicine (MindMed) Inc.'s Chief Legal Officer, Mark Sullivan, sold 11,278 common shares at $9.77 each to cover tax obligations related to vested restricted stock units.
Mind Medicine (MindMed) Inc. CEO Robert Barrow sold 25,797 common shares at $9.77 each to cover tax obligations, as part of a pre-arranged 10b5-1 plan.
Mind Medicine (MindMed) Inc.'s Chief Medical Officer, Daniel Karlin, sold 7,704 common shares to cover tax obligations related to vested restricted stock units.